New drug candidate prolongs the lives of pancreatic cance...(t study researchers tested for both toxi...),Health
Navigation Links
New drug candidate prolongs the lives of pancreatic cancer patients
Date:7/20/2009
t study, researchers tested for both toxicity and effectiveness. They gave 19 patients with advanced pancreatic cancer daily doses of salirasib along with a standard gemcitabine regimen. Salirasib was well tolerated by the patients, and they surpassed on average the number of months they would have lived on gentamiacine alone. There were no toxic side effects, such as heart or lung ailments. Tumor biopsies showed a significant reduction in Ras levels, suggesting that the drug is inhibiting the action of Ras in the tumor itself.
For this study, Salirasib was licensed by Concordia Pharmaceuticals, which collaborated with the Memorial Sloan Kettering Cancer Center, Johns Hopkins, the M.D. Anderson Cancer Center and other institutes in the United States.
If Phase II/III trials are successful, Prof. Kloog's drug will be the first successful Ras antagonist known to medical science. Salirabib could be medically available in as little as two years.
'/>"/>
| Contact: George Hunka ghunka@aftau.org 212-742-9070 American Friends of Tel Aviv University Source:Eurekalert |
Related medicine news :
1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. U.S. Physicians Question Presidential Candidates
5. Schizophrenia candidate genes affect even healthy individuals
6. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
9. 1 in 5 bariatric surgery candidates not psychologically cleared for surgery
10. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
(Date:11/20/2009)...ON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRYST P...l Meeting of Shareholders will be held on Monday, ...o consider approval of two special resolutions. Th...rize the sale of all or substantially all of the a...ded for in the asset purchase agreement dated Nove...
(Date:11/20/2009)...HINGTON, Nov. 20 The Un...he Senate to make essential changes its health ref...abortion funding and conscience protection on abor... and include strong provisions for adequate afford...h care bill an "enormous disappointment" that crea...
(Date:11/20/2009)... Senators and Congressmen in Competitive Re-...alth Care Vote , Washingt...ongressmen running for re-election next year in ra...rlie Cook, may come to regret voting for House Spe...ing to a breaking Zogby International/ O’Lea...
(Date:11/20/2009)... Nov. 20 The American D...and Drug Administration (FDA) to establish appropr.... ,, Citing concern about the safety of whiten...he benefit of professional consultation or examina...pplication of chemically based tooth whitening or ...
(Date:11/20/2009)...AIFA, Israel, November 20 /PRNewswire-FirstCall/ -... http://www.CVSLMEDICAL.COM , a leading,developer ...ay announced that,the company,s Board of Directors...rope, Canada and the Far East for its proprietary ...or all angioplasty (PCTA) procedures. , C...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2[0] NUCRYST Announces Special Meeting of Shareholders[0] U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability[0] Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill [0] American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products[0] Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East
... new weapon is being investigated.//
Scientist...edient -oligo fructose, on obese human subjects. ...the natural fiber seen in baby foods, cereals and ...ke peptide that was responsible for a feeling of s...
...munication between clinicians in the Intensive Car... significantly reduces feelings of stress,// anxie...g to a study that appears in the February 1, 2007 ...National Institutes of Health (NIH), showed that t...
...vels during women’s menstrual cycles affect the re... imaging study at the National Institute of// Ment...itutes of Health (NIH), has revealed.
While w...o a phase when estrogen and progesterone are prese...
...to grant product patent for Glivec, the cancer dru...esult Novartis may not be able to conduct// their ...re the countries where Novartis conducts its resea... government could hamper the launch of their paten...
...re has been a marked increase in allergic reaction...ed eight times during a 30 year period.// Teenager...sporting different hair colors, in keeping with a ...esearchers are pressing for a wider debate about t...
...of Michigan Medical Center have, for the first tim.../ Their work indicates that these cells are likely...ression, and metastasis that define this deadly ca...atic cancer in half of mice tested. They also foun...
Other Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 3(Date:11/20/2009)... , NEW YORK, Nov. 20 ,, Re...h report is available in its catalogue. ,, Glo... http://www.reportlinker.com/p0164741/Global-Mark...=prnewswire&utm_medium=pr&utm_campaign=prn...sy devices includes the spring loaded core needle ...
(Date:11/20/2009)..., NATICK, Mass. and LONDON, Nov. 20 /PRNewswire...: BSX ) today announced that it has received 510...ration (FDA) and CE Mark approval to market its Wa...e treatment of malignant esophageal strictures (ob...ctable or non-resectable esophageal cancer. ,,...
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-U...mes article that questions why currently availabl...ancers are being ignored, ECRI Institute, an indep...ap to the evidence on Finasteride for Prevention ... November 13, 2009, New York Times article, " Dr...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Heartburn Drugs May Contribute to the Problem 50969 1Heartburn Drugs May Contribute to the Problem 50969 2Heartburn Drugs May Contribute to the Problem 50969 3Pharmacyclics Sets Record Date for Rights Offering 50966 1Pharmacyclics Sets Record Date for Rights Offering 50966 2Pharmacyclics Sets Record Date for Rights Offering 50966 3CareFusion Corporation Launches International Jazz Festival Series 50963 1CareFusion Corporation Launches International Jazz Festival Series 50963 2CareFusion Corporation Launches International Jazz Festival Series 50963 3CareFusion Corporation Launches International Jazz Festival Series 50963 4CareFusion Corporation Launches International Jazz Festival Series 50963 5[0] Reportlinker Adds Global Markets for Breast Biopsy Devices 2009[0] Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent[0] ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists
... (OTCBB: ORMP) ( http://www.oramed.com ), a develo... it will hold a conference call on August 6,2008 a... 2A clinical trials,of its flagship product, ORMD ... trial is focused on assessing the safety and effi... the successfully completed,Phase 1 studies in Isr...
...(OTC Bulletin Board: ANPG), reported today that it...I) announced that its EnviroTru(R),disinfectant ha...tment of,Management Services (DMS) in the State of...r, A World of Green, LLC(TM) ( http://www.aworldo...u(R) assigned under the code which now,permits Sta...
Other Medicine Technology:Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |